LA JOLLA, Calif., November 13, 2013 – Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2013 and provided a summary of recent corporate highlights.
Help employers find you! Check out all the jobs and post your resume.
